Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -37.42% | -37.42% | -- | -- | -11.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -136.84% | -136.84% | -- | -- | 55.81% |
| Total Operating Expenses | -32.89% | -32.89% | -- | -- | 7.16% |
| Operating Income | 32.89% | 32.89% | -- | -- | -7.16% |
| Income Before Tax | 64.63% | 64.63% | -- | -- | 4.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 64.63% | 64.63% | -- | -- | 4.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.63% | 64.63% | -- | -- | 27.00% |
| EBIT | 32.89% | 32.89% | -- | -- | -7.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 85.47% | 85.47% | 95.96% | 95.96% | 92.56% |
| Normalized Basic EPS | 85.34% | 85.34% | -- | -- | 90.30% |
| EPS Diluted | 85.47% | 85.47% | 95.96% | 95.96% | 92.56% |
| Normalized Diluted EPS | 85.34% | 85.34% | -- | -- | 90.30% |
| Average Basic Shares Outstanding | 143.47% | 143.47% | 633.54% | -- | 881.29% |
| Average Diluted Shares Outstanding | 143.47% | 143.47% | 633.54% | 1,616.14% | 881.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |